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The  way  in which the European Community  impinges 
on the operations·of the profession of pharmacy  and the 
pharmaceutical industry provides  a  good  example of how 
adaptable and  flexible  the  Community  is in practice -
and how  it. is. always  ready to learn from experience-
and profit from its m!stakes. 
One  of  th~ big changes  that has. taken place 
withi~_ the Community  over recent  year_~ ,is the reaction 
against any idea of harmonisation for harmonisation's  .. 
sake.  Back  in 1969,and again in 1972,  the 'European 
Commission  put forward  ambitious  proposals .for the 
imposition of an identical professional'statute for 
pharmacists within the  then Community.  Even within the  .. 
six founding members>  with their long experience of the 
Community,  this ran into serious difficulties.  And 
when  the· three new  members  arrived,. the1.task was  given 
up  as  politically impossible. 
'  Since then,  there has. grown up  a  new  and more 
\ 
pragmatic approach to the problems of harmonisation  ~ 
seeking the minimum  essential for  the. development of 
the Community  or for public health_and safety,  and 
making  the  arrangements  optional wherever possible. 
There is now  no  question - and indeed there 
never was  - of us all being forced to drink the  same 
Euro-beer and  eat the  same  Euro-bread.  Nor  is there 
any  danger of all 'of you  being forced  to  become 
exactly the same  kind of Euro-pharmacist,  although 
there may  be much  more  to be  said for  serving the  , 
same  Euro-aspirin,  conformifg to the  same  Community 
safety standards. 
.. 
2. The  new  draft directive which the Commission is 
now  proposing,to deal with the difficult and delicate 
question of the free movement  of pharmacists  with~n the 
Cornmunity.will  be  shaped as  a  result of current discussions 
between the Commission  and  the four  ~uropean  .. groupings  of 
pharmaceutical associations.  This  includes  the Groupement 
Pharmaceutique,  to which your Society,  Mr.  Chairman, 
~elongs.  The  Commission has already circulated its 
proposals-in writing,  and hopes  to have  the comments 
of the European organisations  by  the end of the year. 
As  you know,  some  progress has already been 
made  in a  related field,  that of the free movement  of 
pharmaceutical  products.  The  second Direc.ti  ve  on the 
free movement  of pl)armaceutical  products ·.and  their 
licens_ing in the Member  States was  a<!_opted  by the 
Council  in,May 1975  and will come  into operation in 
..  . 
November  of this year.  It included minimum  qualifications 
for persons responsible for manufacturing·· pharmaceutical 
products and certifying them at the m~~facturing stage. 
These minimum  qualifications  ~ so many  years  of 
theoretical and practical training - will serve as  the 
basis for  th~ free movement  of pharmacists  in the  ,. 
Commission's forthcoming draft  Directive~· which will 
also deal with the other side ·of_  ~he. coin,  namely  the 
DB.ltual  recognition of these minimum  qu~lifications. 
The  Commission  intends to draw·up its draft Directive 
in the course of next year,  and,  as  I  have  said, will 
make  it one  of its priority tasks. 
The  Community  has also been becoming increasingly 
act~ve in the  field of consumer protection - ensuring 
t~at the customer in the pharmacy is protected in terms 
of value for money..  There is a  new  Community  Consumer 
Department,  devoted_ to ensuring clear labelling and 
agreed safety standards. 
The  Commission also has  important  powers  to 
ensure that the consumer  does  not suffer in price and 
choice  from  any large  comp~ny abusing any  dominant 
.. 
4. position it may  occupy in its own  field.  In the 
case of Hoffmann-La Roche,  the  Commission recently 
imposed  a  £125,000  fine  and ordered the company  to 
stop  cer~ain practices considered to constitute an 
abuse of the  firm's  dominant position on  the 
Community's  vitamins market.  In our  view,  the 
practices in question were  aimed at ensuring that 
a  number  of major bulk vitamin users in the Community 
purchased their vitamins only from Hoffmann-La  Roche, 
thereby cutting out competition from other vitamin 
producers  to the detriment of the industry and  the 
consumer.  Some  of the contracts to which we  objected 
contained an express obligation  b~ the producer to buy 
all or almost all of their vitamins  from  Roche.  Others 
provided for  fidel~ty rebates, whereby reoates were 
granted based not  on differences in costs related to 
quantities supplied,  but  based on  th~ supply by  Roche 
of all,  or a  very large  proport~on of the customers'  . 
requirements.  However,  Hoffmann-La  ~och~. ~as appealed 
to the  Court of Justice .against our decision,  and the 
final word will rest with the Court. 
Meanwhile,  the  Commission is pursuing a  number 
of other investigations in the interests of ensuring 
for the  ~bl~c a  fair degree of freedom of choice and 
protection from unfair price policies. 
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